Profiel
Leslie Aberman worked as Senior Director-Intellectual Property at Seagen Inc. from 2015 to 2015.
Prior to that, Aberman worked as Associate General Counsel at Infectious Disease Research Institute.
Currently, Aberman is Vice President-Legal Affairs at Neoleukin Therapeutics, Inc. from 2019 to 2023.
Aberman completed an undergraduate degree at Brown University and a graduate degree at Columbia Law School.
Eerdere bekende functies van Leslie Aberman
| Bedrijven | Functie | Einde |
|---|---|---|
| NEUROGENE INC. | Algemeen Adviseur | 01-03-2023 |
| SEAGEN INC. | Corporate Officer/Principal | 01-03-2015 |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Algemeen Adviseur | - |
Opleiding van Leslie Aberman
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Commercial Services |
Columbia Law School
Columbia Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
















